Generate Biomedicines (GENB) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Generate Biomedicines had return on equity of -81.7%, debt-to-equity of 0.36 (up from 0.22), a current ratio of 2.85 (down from 4.70) and return on assets of -34.6%. A current ratio of 2.85 means current assets exceed current liabilities.

Generate Biomedicines Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024
Period ending	Dec 2025	Dec 2024
Valuation Ratios
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)	-81.72%	-
Return on Assets (ROA)	-34.63%	-
Return on Capital Employed (ROCE)	-94.80%	-45.60%
Leverage & Solvency Ratios
Debt/Equity	0.36	0.22
Liquidity Ratios
Current Ratio	2.85	4.70
Quick Ratio	2.69	4.55
Efficiency Ratios
Asset Turnover	0.07	-
Yield & Distribution Ratios
Buyback Yield	-2.77%	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Generate Biomedicines Financial Ratios

What is Generate Biomedicines's return on equity?

Generate Biomedicines's return on equity (ROE) was -81.7% for fiscal 2025 (period ended Dec 31, 2025).

What is Generate Biomedicines's debt-to-equity ratio?

Generate Biomedicines's debt-to-equity ratio was 0.36 for fiscal 2025 (period ended Dec 31, 2025). It was 0.22 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition